Diamyd Phase IIb trial results published in Diabetes Care

Diamyd Phase IIb trial results published in Diabetes Care
STOCKHOLM, May 21, 2021 /PRNewswire/ --
Diabetes Care has published the results of DIAGNODE-2, a Phase IIb trial that evaluated intralymphatic administration of Diamyd Medical's lead drug candidate Diamyd
(GAD-alum) in individuals recently diagnosed with type 1 diabetes. Results showed, in line with a published large-scale metaanalysis of clinical data, that while no treatment benefit was seen in the full patient population, three intralymphatic injections of Diamyd
had a significant and positive effect on the preservation of insulin producing capacity in the predefined subgroup of individuals that carry the HLA DR3-DQ2 haplotype. In this subgroup of patients, more than 50% greater preservation of insulin producing capacity was observed at 15 months from baseline in those that received active treatment compared to placebo.

Related Keywords

Sweden ,Czech Republic ,Netherlands ,Stockholm ,Spain ,Uppsala ,Uppsala Lan ,Mark Atkinson ,Ulf Hannelius ,Johnny Ludvigsson ,Diabetes Research Institute ,University Of Florida ,Company European Phase Iib ,Uppsala University Hospital ,Company Certified Adviser ,Diamyd Medical ,Diamyd Medical Board ,Professor Johnny Ludvigsson ,European Phase ,Uppsala University ,Nextcell Pharma ,Nasdaq First North Growth Market ,Certified Adviser ,Diamyd ,Hase ,Trial ,Results ,Published ,Diabetes ,Mare ,ஸ்வீடந் ,செக் குடியரசு ,நெதர்லாந்து ,ஸ்டாக்‌ஹோல்ம் ,ஸ்பெயின் ,குறி அட்கின்சன் ,நீரிழிவு நோய் ஆராய்ச்சி நிறுவனம் ,பல்கலைக்கழகம் ஆஃப் புளோரிடா ,நிறுவனம் ஐரோப்பிய கட்டம் இயைப் ,ஐரோப்பிய கட்டம் ,நாஸ்டாக் முதல் வடக்கு வளர்ச்சி சந்தை ,ரியால் ,உள்ளன ,